Fantastic. That is all I need.
We have an innovation system that is broken, but we still have the possibility of transforming the financial incentives for innovation. Instead of just plowing more money in the current system, we need to rethink the way we use that public money right now in order to reorient the research niche, which could be made more promising in terms of innovative therapeutics.
For example, public research is so important right now. We always try to articulate public research with commercial needs. Right now the business model for commercial needs is still focusing on me-too drugs that represent no therapeutic—